Gastrointestinal Cancer News

Neoadjuvant gemcitabine-based chemoradiotherapy prolonged OS compared with upfront surgery among patients with resectable and borderline resectable pancreatic cancer, according to phase 3 study results in Journal of Clinical Oncology.

THOROFARE, NJ — Healio is set to host the inaugural hematology/oncology Disruptive Innovators Award Reception during the American Society of Clinical Oncology Annual Meeting. The event will take place on June 4, 2022, at the Hyatt Regency McCormick Place in Chicago, Illinois.

Worldwide prevalence of sporadic colorectal cancer— long viewed as a disease of older individuals — has increased steadily among those aged younger than 50 years during the past decade, according to a review paper in The Lancet Oncology.

Click here to read the Cover Story, “ Pandemic proves telehealth ‘works in saving lives’ and ‘that we have an inequitable system’ ”

Over the last decade, “telehealth” became a buzzword in conversations about health care innovation.

Novartis temporarily suspended production at two of its radioligand therapy production sites.

Colorectal cancer is the third leading cause of cancer-related deaths in the United States, for both men and women, and across the entire population represents the second most common cause of cancer deaths and diagnoses.

Women who initiated endoscopy screening before age 50 years demonstrated a significantly reduced risk for colorectal cancer than women who did not undergo endoscopy, according to study results published in JAMA Oncology.

Gemcitabine and cisplatin plus durvalumab, with or without tremelimumab, produced favorable outcomes as first-line treatment for advanced biliary tract cancer, according to research.

The FDA granted priority review to durvalumab plus chemotherapy for treatment of locally advanced or metastatic biliary tract cancer.